Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.2 AUD | -.--% | +5.26% | +11.11% |
Apr. 23 | Microba's Revenue Climbs 297% in Fiscal Q3 | MT |
Apr. 10 | Microba Life Sciences Secures AU$6 Million Tax Rebate for Fiscal Year 2023; Shares Fall 5% | MT |
Sales 2024 * | 11.81M 7.86M | Sales 2025 * | 17.97M 11.95M | Capitalization | 89.57M 59.58M |
---|---|---|---|---|---|
Net income 2024 * | -17M -11.31M | Net income 2025 * | -16M -10.64M | EV / Sales 2024 * | 5.85 x |
Net cash position 2024 * | 20.45M 13.6M | Net cash position 2025 * | 17.07M 11.35M | EV / Sales 2025 * | 4.04 x |
P/E ratio 2024 * |
-5.13
x | P/E ratio 2025 * |
-5.22
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 57.75% |
1 week | +5.26% | ||
1 month | +8.11% | ||
3 months | +11.11% | ||
6 months | -4.76% | ||
Current year | +11.11% |
Managers | Title | Age | Since |
---|---|---|---|
Luke Reid
CEO | Chief Executive Officer | - | - |
James Heath
DFI | Director of Finance/CFO | - | - |
Yao Liu
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Mark Capone
BRD | Director/Board Member | 61 | 21-03-17 |
Director/Board Member | - | 22-09-07 | |
Hyung-Tae Kim
BRD | Director/Board Member | 61 | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 0.2 | -.--% | 23,969 |
24-05-30 | 0.2 | -.--% | 30,378 |
24-05-29 | 0.2 | +2.56% | 127,089 |
24-05-28 | 0.195 | -.--% | 51,293 |
24-05-27 | 0.195 | +2.63% | 65,797 |
Delayed Quote Australian S.E., May 31, 2024 at 01:58 am EDT
More quotesEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+11.11% | 59.47M | |
-24.16% | 7.76B | |
+68.65% | 4.33B | |
+2.72% | 2.63B | |
-2.98% | 2.64B | |
-46.17% | 2.16B | |
-15.27% | 1.75B | |
-22.12% | 1.46B | |
+13.62% | 1.17B | |
-43.81% | 1.14B |
- Stock Market
- Equities
- MAP Stock